PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+10.51%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$8.55M
(+9%)
Cap. Flow
+$7.51M
Cap. Flow
% of AUM
7.22%
Top 10 Holdings %
Top 10 Hldgs %
35.65%
Holding
124
New
22
Increased
30
Reduced
40
Closed
12
Avg Time Held
2
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEAR
TearLab Corporation
TEAR
|
+$1.85M |
| 2 |
Flexion Therapeutics, Inc.
FLXN
|
+$1.31M |
| 3 |
Target
TGT
|
+$1.13M |
| 4 |
Ring Energy
REI
|
+$1.03M |
| 5 |
Tactile Systems Technology
TCMD
|
+$979K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axogen
AXGN
|
+$1.07M |
| 2 |
Entellus Medical, Inc. Common Stock
ENTL
|
+$1.05M |
| 3 |
ZAGG
ZAGG Inc Common Stock (Delaware)
ZAGG
|
+$1.05M |
| 4 |
Cencora
COR
|
+$976K |
| 5 |
CryoPort
CYRX
|
+$602K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.46% |
| 2 | Technology | 10.82% |
| 3 | Industrials | 9.42% |
| 4 | Financials | 4.89% |
| 5 | Consumer Staples | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Axogen
AXGN
$2.09B
| $14M | 13.45% |
494,150
-45,448
| -8% | -$1.07M |
2013 Q3
17 quarters
|
|
2
Abbott
ABT
$178B
| $4.62M | 4.44% |
80,950
-2,110
| -3% | -$117K |
2014 Q1
15 quarters
|
|
3
Vericel Corp
VCEL
$2.05B
| $3.15M | 3.03% |
578,950
+16,350
| +3% | +$75.4K |
2014 Q3
13 quarters
|
|
4
NeoGenomics
NEO
$2.17B
| $2.64M | 2.54% |
297,850
-10,450
| -3% | -$96.4K |
2013 Q2
18 quarters
|
|
5
Rockwell Medical
RMTI
$31.6M
| $2.51M | 2.41% |
3,917
-65
| -2% | -$45.8K |
2013 Q2
18 quarters
|
|
6
LeMaitre Vascular
LMAT
$1.89B
| $2.19M | 2.1% |
68,700
-8,375
| -11% | -$287K |
2017 Q1
3 quarters
|
|
7
Pfizer
PFE
$167B
| $2.1M | 2.02% |
61,062
+6,324
| +12% | +$216K |
2013 Q2
18 quarters
|
|
8
Idexx Laboratories
IDXX
$41.5B
| $2.09M | 2.01% |
13,350
-650
| -5% | -$102K |
2013 Q3
17 quarters
|
|
9
AbbVie
ABBV
$502B
| $1.96M | 1.89% |
20,300
+750
| +4% | +$70.7K |
2014 Q3
13 quarters
|
|
|
VYNT
10
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $1.83M | 1.76% |
6,598
+1,220
| +23% | +$465K |
2015 Q4
8 quarters
|
|
11
Microsoft
MSFT
$3.98T
| $1.8M | 1.73% |
21,060
-125
| -0.6% | -$10.3K |
2014 Q1
15 quarters
|
|
12
Eli Lilly
LLY
$1.08T
| $1.76M | 1.7% |
20,900
+2,700
| +15% | +$230K |
2013 Q2
18 quarters
|
|
13
ANI Pharmaceuticals
ANIP
$1.64B
| $1.74M | 1.67% |
27,000
+7,200
| +36% | +$448K |
2017 Q1
3 quarters
|
|
14
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.67M | 1.6% |
529,562
-31,319
| -6% | -$90.3K |
2015 Q2
10 quarters
|
|
15
Digital Turbine
APPS
$1.17B
| $1.64M | 1.57% |
914,480
+3,400
| +0.4% | +$5.59K |
2015 Q1
11 quarters
|
|
16
AtriCure
ATRC
$2.9B
| $1.61M | 1.55% |
88,550
-4,400
| -5% | -$87.1K |
2013 Q2
18 quarters
|
|
17
Aflac
AFL
$58.8B
| $1.51M | 1.45% |
34,400
+3,500
| +11% | +$149K |
2015 Q2
10 quarters
|
|
18
Integer Holdings
ITGR
$4.31B
| $1.45M | 1.4% |
32,100
-1,450
| -4% | -$70.6K |
2016 Q4
4 quarters
|
|
|
CSII
19
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.45M | 1.39% |
61,000
-5,550
| -8% | -$140K |
2013 Q2
18 quarters
|
|
|
20
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $1.34M | 1.29% |
+53,500
| New | +$1.31M |
2017 Q4
0 quarters
|
|
21
CareDx
CDNA
$3.38B
| $1.31M | 1.26% |
178,639
+40,089
| +29% | +$250K |
2017 Q3
1 quarter
|
|
22
Donaldson
DCI
$10.1B
| $1.3M | 1.25% |
26,650
+11,650
| +78% | +$555K |
2013 Q2
18 quarters
|
|
23
Bristol-Myers Squibb
BMY
$120B
| $1.24M | 1.19% |
20,175
+2,650
| +15% | +$166K |
2017 Q3
1 quarter
|
|
24
AT&T
T
$157B
| $1.23M | 1.18% |
41,920
+1,986
| +5% | +$54.2K |
2015 Q3
9 quarters
|
|
|
BBQ
25
DELISTED
BBQ Holdings, Inc. Common Stock
BBQ
| $1.23M | 1.18% |
187,600
+12,500
| +7% | +$59.3K |
2016 Q4
4 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Perkins Capital Management held 124 positions worth $104M, up 9% from $95.4M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management deployed $7.51M of net new capital in Q4 2017, opening 22 new positions and adding to 30 existing holdings. Its largest new stake was Flexion Therapeutics, Inc.: 53,500 shares worth $1.34M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Axogen, an estimated $1.07M trimmed.
- Perkins Capital Management's largest Q4 2017 buy was Flexion Therapeutics, Inc.: 53,500 shares worth $1.34M.
- Perkins Capital Management added most to TearLab Corporation in Q4 2017, an estimated $1.85M increase.
- Perkins Capital Management's biggest Q4 2017 reduction was Axogen, cutting an estimated $1.07M.
- Perkins Capital Management fully exited Entellus Medical, Inc. Common Stock in Q4 2017, selling an estimated $1.05M.
- Perkins Capital Management's ten largest holdings make up 36% of its $104M portfolio in Q4 2017.
- Perkins Capital Management opened 22 new positions and closed 12 in Q4 2017.
- Perkins Capital Management's portfolio value rose 9% quarter-over-quarter to $104M.
Based on Perkins Capital Management's 13F filing for Q4 2017, filed 26 Jan 2018.